Get Thin MD review

What it is

Get Thin MD, operating as Get Thin MD LLC from getthinusa.com, is a nationwide asynchronous telehealth platform. Its weight-loss line runs compounded semaglutide and tirzepatide plus brand-name Ozempic and Zepbound; its muscle-growth line offers sermorelin injections and a sermorelin oral dropper; its anti-aging line offers NAD⁺ injections and an NAD⁺ nasal spray. It also sells estradiol-based hormone therapy, hair-growth products and a biomarker panel. No insurance is accepted and no in-person visit is required.

How it works

Asynchronous by default: you complete an online evaluation, a licensed provider reviews it, and if treatment is appropriate the medication ships. The monthly cost is described as covering the prescription medication, the provider review, a personalized treatment plan, ongoing care coaching and free expedited shipping, which is a clean structure that makes it easy to compare against providers billing those separately. The biomarker panel it sells is a real addition for anyone starting a growth-hormone-axis peptide, though it is a separate purchase rather than part of the default pathway and no baseline lab requirement is described. The gaps are the familiar ones. No compounding pharmacy is named. No formal state list backs the "available nationwide" header, so eligibility is confirmed at intake. And its headline outcome claim — an average loss in the first 30 days — comes from self-reported patient data rather than a trial, which the platform's own footnote says outright and which should be read as marketing rather than evidence.

Pricing transparency

Published for the peptide line, which is the reason to look. Sermorelin injections and the oral dropper are advertised as low as $129 a month, NAD⁺ treatments at the same entry figure, both on a three-month plan, with the shorter terms costing more. Its central pricing claim is a flat one: same price at every dose, no hidden fees, and its own copy states the price will never increase no matter what dose you are on. On providers whose cost scales with the dose, titrating upward can substantially raise a monthly bill over a course, so a flat commitment is a real structural advantage rather than a slogan. The GLP-1 side sits at $169 a month on a three-month plan and $199 billed monthly for compounded semaglutide, $299 for compounded tirzepatide, with promotional sale rates advertised at times — those are order-level discounts, not standing plan rates, and the same caution applies to any peptide promotion. Ask what the sermorelin or NAD⁺ price is month-to-month rather than on the three-month plan, and confirm the flat-dose promise applies to the peptide line in writing.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Get Thin MD publishes the disclaimer verbatim — its own copy states the FDA does not review or approve any compounded medications for safety or effectiveness — and describes prescriptions as filled through state-licensed pharmacies without naming them. Compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are, so an unnamed compounder remains a substantive question. On the evidence, the two wellness lines are not equivalent and the site does not distinguish between them. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, but the long-term human outcome data stays thin and no controlled trial demonstrates the muscle-growth results the line is marketed under; the oral dropper route has no comparative bioavailability data published here. Injected and intranasal NAD⁺ have no controlled human outcome trials at all; the NAD⁺ forms with human data are the oral precursors NR and NMN, and what they demonstrate is a raised blood NAD⁺ level rather than an improved outcome. Individual results vary.

Pros and watch-outs

The evidence behind what Get Thin MD prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Get Thin MD compares

A few alternatives worth a look, depending on what you’re optimizing for.

• CoreAge Rx

  Injected or intranasal NAD⁺ at a published price across 50 states

  See CoreAge Rx →
• Telos RX

  Choice of GLP-1 formats, including needle-free sublingual tirzepatide

  See Telos RX →
• Invigor Medical

  Prescription at-home NAD⁺ injections via telehealth

  See Invigor Medical →